Abbott Wins Antitrust Challenge Over HIV Drug Cocktail

Law360, New York (July 27, 2006, 12:00 AM EDT) -- When patent owners raise prices and make combination products more expensive in the process, they cannot be sued for monopoly leveraging under U.S. antitrust laws, according to a ruling Wednesday by the U.S. Court of Appeals for the Seventh Circuit.

With the ruling, Judge Frank H. Easterbrook affirmed a lower court’s decision that drug maker Abbott Laboratories Inc. wasn’t violating the Sherman Act when it jacked up the price for its component of a treatment for acquired immune deficiency syndrome.

The class action legal battle surrounds...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.